Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
Nate Raymond·
·1 min read
·
0 reactions
·
0 comments
·
17 views
The verdict is the first time a jury has found a pharmaceutical company liable in class-action litigation over what is called a 'pay-for-delay' agreement with generic rivals.
Original article
Japan Times · Nate Raymond
Opening excerpt (first ~120 words) tap to expand
Takeda Pharmaceutical headquarters in Tokyo. The company said it will "vigorously pursue" an appeal after a U.S. jury on Monday found the company liable for causing about $885 million in damages by delaying a generic version of its constipation drug through an anticompetitive scheme. | BLOOMBERG
Excerpt limited to ~120 words for fair-use compliance. The full article is at Japan Times.
Anonymous · no account needed
Discussion
0 commentsMore from Japan Times
Japan’s department stores gear up for summer-gift season
Japan Times·19
Japan promotes preconception care amid falling birthrates
Japan Times·20
Leclerc confirms multi-year extension with Ferrari
Japan Times·18
Suspect in Tochigi robbery-murder who fled abroad ordered to return passport
Japan Times·19
Trump proposes new levies of at least 10% to rebuild tariff wall
Japan Times·28
Japan’s births hit new low, but drop less severe than previous years
Japan Times·25